

# CITATION REPORT

List of articles citing

**Drug reactions, enzymes, and biochemical genetics :  
50 years later**

**DOI: 10.2217/14622416.8.11.1479**

**Pharmacogenomics, 2007, 8, 1479-84.**

**Source:** <https://exaly.com/paper-pdf/41663118/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Race as a variable in pharmacogenomics science: from empirical ethics to publication standards. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 837-41	1.9	4
27	Pharmacogenetics in Europe: barriers and opportunities. <i>Public Health Genomics</i> , <b>2009</b> , 12, 134-41	1.9	43
26	Application of principal component analysis to pharmacogenomic studies in Canada. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 362-72	3.5	20
25	Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1309-22	2.6	32
24	Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. <i>OMICS A Journal of Integrative Biology</i> , <b>2009</b> , 13, 43-61	3.8	45
23	Genome-environment interactions and prospective technology assessment: evolution from pharmacogenomics to nutrigenomics and ecogenomics. <i>OMICS A Journal of Integrative Biology</i> , <b>2009</b> , 13, 1-6	3.8	14
22	TPMT testing in azathioprine: a cost-effective use of healthcare resources?. <i>Personalized Medicine</i> , <b>2009</b> , 6, 103-113	2.2	18
21	MicroRNAs and pharmacogenomics. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 629-32	2.6	57
20	Pharmacogenetics education: 10 years of experience at Tel Aviv University. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 647-9	2.6	16
19	History of Human Genetics*. <b>2010</b> , 13-29		3
18	Genetic heterogeneity in human disease. <i>Cell</i> , <b>2010</b> , 141, 210-7	56.2	737
17	MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. <i>Trends in Molecular Medicine</i> , <b>2011</b> , 17, 412-23	11.5	100
16	Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1051-9	2.6	11
15	Automatic filtering and substantiation of drug safety signals. <i>PLoS Computational Biology</i> , <b>2012</b> , 8, e1002457	3.457	30
14	PCOS and peripheral AMH levels in relation to FSH receptor gene single nucleotide polymorphisms. <i>Gynecological Endocrinology</i> , <b>2012</b> , 28, 375-7	2.4	12
13	Analysis of chemical and biological features yields mechanistic insights into drug side effects. <i>Chemistry and Biology</i> , <b>2013</b> , 20, 594-603		34
12	Pharmacogenomics in early-phase clinical development. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1085-97	2.6	37

11	Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen. <i>Personalized Medicine</i> , <b>2013</b> , 10, 601-611	2.2	2
10	Drug-induced acute myocardial infarction: identifying prime suspects from electronic healthcare records-based surveillance system. <i>PLoS ONE</i> , <b>2013</b> , 8, e72148	3.7	35
9	The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. <i>Value in Health</i> , <b>2014</b> , 17, 22-33	3.3	56
8	Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 2627-34	4.4	15
7	Pharmacogenomics, human genetic diversity and the incorporation and rejection of color/race in Brazil. <i>BioSocieties</i> , <b>2015</b> , 10, 48-69	1.5	15
6	The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 401-4	6.1	7
5	The influence of genetic constitution on migraine drug responses. <i>Cephalalgia</i> , <b>2016</b> , 36, 624-39	6.1	27
4	Pharmacogenetics of therapeutics. <b>2019</b> , 41-74		
3	Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?. <i>Pharmacogenomics Journal</i> , <b>2021</b> , 21, 47-59	3.5	2
2	Ethical Considerations in the Genomic Era. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , <b>2015</b> , 349-375	0.4	0
1	PRECISION MEDICINE: FROM DILOTYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , <b>2018</b> , 23, 389-399	1.3	